Stockreport

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting [Yahoo! Finance]

Monopar Therapeutics Inc.  (MNPR) 
PDF developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead radiopharma program MNPR [Read more]